Inherited thrombocytopenias—recent advances in clinical and molecular aspects

Carlo L. Balduini, Federica Melazzini, Alessandro Pecci

Research output: Contribution to journalReview article

Abstract

Since the beginning of the century, our knowledge of inherited thrombocytopenias greatly advanced, and we presently know 30 forms with well-defined genetic defects. This great advancement changed our view of these disorders, as we realized that most patients have only mild thrombocytopenia with inconspicuous bleeding or no bleeding tendency at all. However, better knowledge of inherited thrombocytopenias also revealed that some of the most prevalent forms expose to the risk of acquiring during infancy or adulthood additional disorders that endanger the life of patients much more than hemorrhages. Thus, inherited thrombocytopenias are complex disorders with quite different clinical features and prognosis. Identification of novel genes whose mutations result in low platelet count greatly advanced also our knowledge of the megakaryocyte biology and proved beyond any doubt that the defective proteins play an essential role in platelet biogenesis or survival in humans. Based on the study of inherited thrombocytopenias, we better understood the sequence of molecular events regulating megakaryocyte differentiation, maturation, and platelet release. Since nearly 50% of patients have as yet unidentified genetic or molecular mechanisms underlying their inherited thrombocytopenia, further studies are expected to reveal new clinical entities and new molecular mechanisms of platelet production.

Original languageEnglish
Pages (from-to)3-13
Number of pages11
JournalPlatelets
Volume28
Issue number1
DOIs
Publication statusPublished - Jan 2 2017

Fingerprint

Megakaryocytes
Blood Platelets
Hemorrhage
Thrombocytopenia
Platelet Count
Molecular Biology
Mutation
Survival
Genes
Proteins

Keywords

  • Bleeding
  • inherited thrombocytopenias
  • megakaryocytes
  • platelets

ASJC Scopus subject areas

  • Hematology

Cite this

Inherited thrombocytopenias—recent advances in clinical and molecular aspects. / Balduini, Carlo L.; Melazzini, Federica; Pecci, Alessandro.

In: Platelets, Vol. 28, No. 1, 02.01.2017, p. 3-13.

Research output: Contribution to journalReview article

@article{8d1687931edf4f1b8454fd02d5c81344,
title = "Inherited thrombocytopenias—recent advances in clinical and molecular aspects",
abstract = "Since the beginning of the century, our knowledge of inherited thrombocytopenias greatly advanced, and we presently know 30 forms with well-defined genetic defects. This great advancement changed our view of these disorders, as we realized that most patients have only mild thrombocytopenia with inconspicuous bleeding or no bleeding tendency at all. However, better knowledge of inherited thrombocytopenias also revealed that some of the most prevalent forms expose to the risk of acquiring during infancy or adulthood additional disorders that endanger the life of patients much more than hemorrhages. Thus, inherited thrombocytopenias are complex disorders with quite different clinical features and prognosis. Identification of novel genes whose mutations result in low platelet count greatly advanced also our knowledge of the megakaryocyte biology and proved beyond any doubt that the defective proteins play an essential role in platelet biogenesis or survival in humans. Based on the study of inherited thrombocytopenias, we better understood the sequence of molecular events regulating megakaryocyte differentiation, maturation, and platelet release. Since nearly 50{\%} of patients have as yet unidentified genetic or molecular mechanisms underlying their inherited thrombocytopenia, further studies are expected to reveal new clinical entities and new molecular mechanisms of platelet production.",
keywords = "Bleeding, inherited thrombocytopenias, megakaryocytes, platelets",
author = "Balduini, {Carlo L.} and Federica Melazzini and Alessandro Pecci",
year = "2017",
month = "1",
day = "2",
doi = "10.3109/09537104.2016.1171835",
language = "English",
volume = "28",
pages = "3--13",
journal = "Platelets",
issn = "0953-7104",
publisher = "Taylor & Francis",
number = "1",

}

TY - JOUR

T1 - Inherited thrombocytopenias—recent advances in clinical and molecular aspects

AU - Balduini, Carlo L.

AU - Melazzini, Federica

AU - Pecci, Alessandro

PY - 2017/1/2

Y1 - 2017/1/2

N2 - Since the beginning of the century, our knowledge of inherited thrombocytopenias greatly advanced, and we presently know 30 forms with well-defined genetic defects. This great advancement changed our view of these disorders, as we realized that most patients have only mild thrombocytopenia with inconspicuous bleeding or no bleeding tendency at all. However, better knowledge of inherited thrombocytopenias also revealed that some of the most prevalent forms expose to the risk of acquiring during infancy or adulthood additional disorders that endanger the life of patients much more than hemorrhages. Thus, inherited thrombocytopenias are complex disorders with quite different clinical features and prognosis. Identification of novel genes whose mutations result in low platelet count greatly advanced also our knowledge of the megakaryocyte biology and proved beyond any doubt that the defective proteins play an essential role in platelet biogenesis or survival in humans. Based on the study of inherited thrombocytopenias, we better understood the sequence of molecular events regulating megakaryocyte differentiation, maturation, and platelet release. Since nearly 50% of patients have as yet unidentified genetic or molecular mechanisms underlying their inherited thrombocytopenia, further studies are expected to reveal new clinical entities and new molecular mechanisms of platelet production.

AB - Since the beginning of the century, our knowledge of inherited thrombocytopenias greatly advanced, and we presently know 30 forms with well-defined genetic defects. This great advancement changed our view of these disorders, as we realized that most patients have only mild thrombocytopenia with inconspicuous bleeding or no bleeding tendency at all. However, better knowledge of inherited thrombocytopenias also revealed that some of the most prevalent forms expose to the risk of acquiring during infancy or adulthood additional disorders that endanger the life of patients much more than hemorrhages. Thus, inherited thrombocytopenias are complex disorders with quite different clinical features and prognosis. Identification of novel genes whose mutations result in low platelet count greatly advanced also our knowledge of the megakaryocyte biology and proved beyond any doubt that the defective proteins play an essential role in platelet biogenesis or survival in humans. Based on the study of inherited thrombocytopenias, we better understood the sequence of molecular events regulating megakaryocyte differentiation, maturation, and platelet release. Since nearly 50% of patients have as yet unidentified genetic or molecular mechanisms underlying their inherited thrombocytopenia, further studies are expected to reveal new clinical entities and new molecular mechanisms of platelet production.

KW - Bleeding

KW - inherited thrombocytopenias

KW - megakaryocytes

KW - platelets

UR - http://www.scopus.com/inward/record.url?scp=85009829145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009829145&partnerID=8YFLogxK

U2 - 10.3109/09537104.2016.1171835

DO - 10.3109/09537104.2016.1171835

M3 - Review article

C2 - 27161842

AN - SCOPUS:85009829145

VL - 28

SP - 3

EP - 13

JO - Platelets

JF - Platelets

SN - 0953-7104

IS - 1

ER -